Role of Pyroptosis in Endometrial Cancer and Its Therapeutic Regulation

Abdullah Al Mamun1,2, Peiwu Geng1, Shuanghu Wang1

  • 1Key Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, 323000, People's Republic of China.

PubMed

Insights

Pyroptosis, an inflammatory cell death, is implicated in endometrial cancer (EC) progression. Targeting pyroptosis pathways, particularly NLRP3 inflammasome and GSDMD, offers potential for novel EC therapies.

Area of Science:

  • Immunology
  • Cell Biology
  • Oncology

Background:

  • Pyroptosis is a pro-inflammatory programmed cell death pathway mediated by inflammasomes.
  • Dysregulation of pyroptosis and inflammasomes is linked to various diseases, including cancers.
  • Endometrial cancer (EC) progression is associated with aberrant inflammasome and pyroptosis signaling.

Purpose of the Study:

  • To review the molecular mechanisms of pyroptosis in endometrial cancer (EC).
  • To explore the role of pyroptosis-dependent pathways in EC pathogenesis and progression.
  • To discuss the potential of pyroptosis as a therapeutic target for EC.

Main Methods:

  • Literature review of studies on pyroptosis, inflammasomes, and endometrial cancer.
  • Analysis of molecular mechanisms involving NLRP3 inflammasome, caspase-1, and GSDMD in EC.
  • Synthesis of current research on pyroptosis-related signaling pathways in EC development.

Main Results:

  • NLRP3 inflammasome and caspase-1-dependent pyroptosis contribute to EC pathogenesis.
  • Pyroptosis-regulated protein gasdermin D (GSDMD) may serve as an independent prognostic biomarker for EC.
  • Aberrant pyroptosis signaling pathways can drive the progression of EC.

Conclusions:

  • Pyroptosis plays a significant role in the development and progression of endometrial cancer.
  • Targeting pyroptosis pathways presents a promising avenue for developing novel anti-cancer therapies for EC.
  • GSDMD is a potential biomarker for EC prognosis and warrants further investigation.